Deep Sequencing and Analysis of Pharmacogenomic Regions: Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01)

The summary for the Deep Sequencing and Analysis of Pharmacogenomic Regions: Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Deep Sequencing and Analysis of Pharmacogenomic Regions: Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01): Purpose. Genome-wide association studies (GWAS) have been critical for identifying genomic regions associated with addiction phenotypes, and have highlighted several areas that require further refinement using deep sequencing approaches. The goal of this FOA is to support studies proposing to use next-generation sequencing technologies to identify the structural variants and SNP variants with rare to moderate frequencies that affect addiction risk in well-characterized samples with drug abuse phenotypes. Applications may propose strategies for deep sequencing based on family based designs; deep sequencing of regions identified by GWAS to be associated with addiction risk; sequencing candidate genes in individuals with extreme phenotypes; or other analytic approaches that capitalize on the genetic architecture. Applicants must use existing DNA samples with appropriately obtained consents for broad data sharing.

Federal Grant Title:	Deep Sequencing and Analysis of Pharmacogenomic Regions: Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-10-019
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	Apr 29, 2010
Original Application Deadline:	Apr 29, 2010
Posted Date:	Jan 25, 2010
Creation Date:	Jan 26, 2010
Archive Date:	May 30, 2010
Total Program Funding:
Maximum Federal Grant Award:	$250,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...